The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

HHS rehired more than 700 workers at the CDC and over 200 employees at the NIH after restructuring this spring, HHS Secretary ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...